台灣癌症防治網

Endometrial cancer and hormone-replacement therapy in the Million Women study

研究名稱 Endometrial cancer and hormone-replacement therapy in the Million Women study 縮寫或代號 The Million Women study(2) 出處 Lancet 2005；365：1543-51 腫瘤別 Endometrial cancer 研究性質...

Breast cancer and hormone-replacement therapy in the Million Women study

研究名稱 Breast cancer and hormone-replacement therapy in the Million Women study 縮寫或代號 The Million Women study (1) 出處 Lancet 2003；362：419：27 腫瘤別乳癌研究性質...

The Effect of Tibolone in Older Postmenopausal Wome

研究名稱 The Effect of Tibolone in Older Postmenopausal Women 縮寫或代號 LIFT trial 出處 The New England Journal of Medicine 腫瘤別乳癌研究性質研究每日服用1.25mg之tibolone對骨折預防、乳癌及心臟血管之影響，phase 3...

Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms：a double-blind randomized non-inferiority trial

研究名稱 Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms：a double-blind randomized non-inferiority trial 縮寫或代號 LIBERATE trial 出處 Lancet Oncol 2009；10：135-46 腫瘤別乳癌研究性質 Phase 3...

TRIBUTE：a phase III trail of erlotinib hydrochloride（OSI-774）combined with carboplastin and paclitaxed chemotherapy in advanced NSCLC

研究名稱 TRIBUTE：a phase III trail of erlotinib hydrochloride（OSI-774）combined with carboplastin and paclitaxed chemotherapy in advanced NSCLC 縮寫或代號 TRIBUTE 出處 Journal of clinical Oncology：5856-8 腫瘤別 NSCLC 非小細胞肺癌...

EGFR mutation predicts response to gefitinib in patients with NSCLC

研究名稱 EGFR mutation predicts response to gefitinib in patients with NSCLC 縮寫或代號 IPASS(Iressa Pan-Asia study) 出處 ASCO 2009(Abstract 8006) 腫瘤別非小細胞肺癌研究性質...